Progesterone and related progestins: potential new health benefits

References

• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151–7
   PubMed Web of Science ®Google Scholar
• Zegers-Hochschild F, Croxatto HB, Alam V, et al. Endometrial histology and progesterone concentration in women with ovarian failure supplemented with a progesterone vaginal ring. Report on six pregnancy cycles after oocyte donation. Hum Reprod 1996;11:53, Abstract 113
   PubMed Web of Science ®Google Scholar
• Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5–73
   PubMedGoogle Scholar
• Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410–17
   PubMed Web of Science ®Google Scholar
• Chi IC. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Clin Obstet Gynecol 1995;38:872–89
   PubMed Web of Science ®Google Scholar
• Nath A, Sitruk-Ware R. Parenteral administration of progestins for hormonal replacement therapy. Eur J Contracept Reprod Health Care 2009;14:88–96
   PubMed Web of Science ®Google Scholar
• Massai R, Quinteros E, Reyes MV, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005;72:352–7
   PubMed Web of Science ®Google Scholar
• Shaaban MM. Contraception with progestogens and progesterone during lactation. J Steroid Biochem Mol Biol 1991;40:705–10
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao L, She H, et al. Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology 2010;151:5782–94
   PubMed Web of Science ®Google Scholar
• Hussain R, El-Etr M, Gaci O, et al. Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology 2011;152:3820–31
   PubMed Web of Science ®Google Scholar
• Liu A, Margaill I, Zhang S, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology 2012;153:3747–57
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Kumar N, et al. An initial pharmacokinetic study, with a metered dose transdermal system, for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 2007;76:432–8
   PubMed Web of Science ®Google Scholar
• Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65: 571–7
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux A, Bouchard P. The imminent dawn of SPRMs in obstetrics and gynecology. Mol Cell Endocrinol 2012;358:232–43
   PubMed Web of Science ®Google Scholar
• Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73:222–31
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. Climacteric 2007;10:358–70
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95: 403–6
   PubMed Web of Science ®Google Scholar
• Sivin I, Diaz S, Croxatto HB, et al. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception 1997;55:225–32
   PubMed Web of Science ®Google Scholar
• Diaz S, Miranda P, Brandeis A, Cardenas H, Croxatto HB. Mechanism of action of progesterone as contraceptive for lactating women. Ann NY Acad Sci 1991;626:11–21
   PubMedGoogle Scholar
• Diaz S, Cardenas H, Brandeis A, et al. Early difference in the endocrine profile of long and short lactational amenorrhea. J Clin Endocrinol Metab 1991;72:196–201
   PubMed Web of Science ®Google Scholar
• Massai MR, Díaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 2001;64:369–76
   PubMed Web of Science ®Google Scholar
• Toner JP. Vaginal delivery of progesterone in donor oocyte therapy. Hum Reprod 2000;15(Suppl 1):166–71
   PubMedGoogle Scholar
• Zegers-Hochschild F, Balmaceda JP, Fabres C, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod 2000;15:2093–7
   PubMed Web of Science ®Google Scholar
• Levy T, Yairi Y, Bar-Hava I, et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000;65:645–9
   PubMed Web of Science ®Google Scholar
• Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485–90
   PubMed Web of Science ®Google Scholar
• Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000;6:139–48
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Giardina I, Clerici G, et al. The role of progesterone in maternal and fetal medicine. Gynecol Endocrinol 2012;28:925–32
   PubMed Web of Science ®Google Scholar
• Gravett MG, Rubens CE, Nunes TM; GAPPS Review Group. Global report on preterm birth and stillbirth (2 of 7): discovery science. BMC Pregnancy Childbirth 2010;10(Suppl 1):S2
   PubMedGoogle Scholar
• Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci 2010;17:532–9
   PubMed Web of Science ®Google Scholar
• Meis PJ, Kleanoff M, Thom E, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348: 2379–85
   PubMed Web of Science ®Google Scholar
• da Fonseca ED, Bittar RE, Carvahlo MHY, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Vidyadhari D, et al.; for the PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31
   PubMed Web of Science ®Google Scholar
• Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002;187:561–68
   PubMed Web of Science ®Google Scholar
• MacLusky NJ, McEwen BS. Oestrogen modulates progestin receptor concentrations in some rat brain regions but not in others. Nature 1978;274:276–78
   PubMed Web of Science ®Google Scholar
• Sandstrom NJ, Williams CL. Memory retention is modulated by acute estradiol and progesterone replacement. Behav Neurosci 2001;115:384–93
   PubMed Web of Science ®Google Scholar
• Robertson CL, Puskar A, Hoffman GE, et al. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp Neurol 2006;197:235–43
   PubMed Web of Science ®Google Scholar
• Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev 2008;57:386–97
   PubMed Web of Science ®Google Scholar
• Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993;336: 293–306
   PubMed Web of Science ®Google Scholar
• Edwards HE, Epps T, Carlen PL, MacLusky NJ. Progestin receptors mediate progesterone suppression of epileptiform activity in tetanized hippocampal slices in vitro. Neuroscience 2000; 101:895–906
   PubMed Web of Science ®Google Scholar
• Frye CA, Rhodes ME. Estrogen-priming can enhance progesterone's anti-seizure effects in part by increasing hippocampal levels of allopregnanolone. Pharmacol Biochem Behav 2005;81: 907–16
   PubMed Web of Science ®Google Scholar
• Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007;28: 387–439
   PubMed Web of Science ®Google Scholar
• Brinton RD, Thompson RF, Foy MR, et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008;29:313–39
   PubMed Web of Science ®Google Scholar
• Stein DG, Wright DW. Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs 2010;19:847–57
   PubMed Web of Science ®Google Scholar
• Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008;131:318–28
   PubMed Web of Science ®Google Scholar
• Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008;12:R61
   PubMed Web of Science ®Google Scholar
• Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007;49:391–402, 402e1–2
   PubMed Web of Science ®Google Scholar
• Smith C, Al-Nuaimi Y, Wainwright J, et al. The influence of bolus to infusion delays on plasma tissue plasminogen activator levels. Int J Stroke2012 Dec 4. doi: 10.1111/j.1747–4949.2012.00924
   Google Scholar
• Gibson CL, Murphy SP. Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice. J Cereb Blood Flow Metab 2004;24:805–13
   PubMed Web of Science ®Google Scholar
• Sayeed I, Wali B, Stein DG. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor Neurol Neurosci 2007;25:151–9
   PubMed Web of Science ®Google Scholar
• Gibson CL, Coomber B, Murphy SP. Progesterone is neuroprotective following cerebral ischaemia in reproductively ageing female mice. Brain 2011;134:2125–33
   PubMed Web of Science ®Google Scholar
• Parsons B, Rainbow TC, MacLusky NJ, McEwen BS. Progestin receptor levels in rat hypothalamic and limbic nuclei. J Neurosci 1982;2:1446–52
   PubMed Web of Science ®Google Scholar
• Gofflot F, Chartoire N, Vasseur L, et al. Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 2007;131:405–8
   PubMed Web of Science ®Google Scholar
• Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 2006;47:381–9
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65: 629–36
   PubMed Web of Science ®Google Scholar
• Garay L, Gonzalez-Deniselle MC, Lima A, Roig P, De Nicola AF. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 2007;107: 228–37
   PubMed Web of Science ®Google Scholar
• Acs P, Kipp M, Norkute A, et al. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 2009;57:807–14
   Google Scholar
• Koenig HL, Schumacher M, Ferzaz B, et al. Progesterone synthesis and myelin formation by Schwann cells. Science 1995;268:1500–3
   PubMed Web of Science ®Google Scholar
• Ghoumari AM, Ibanez C, El-Etr M, et al. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003;86: 848–59
   PubMed Web of Science ®Google Scholar
• Ghoumari AM, Baulieu EE, Schumacher M. Progesterone increases oligodendroglial cell proliferation in rat cerebellar slice cultures. Neuroscience 2005;135:47–58
   PubMed Web of Science ®Google Scholar
• Franklin RJ, French-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9:839–55
   PubMed Web of Science ®Google Scholar
• Schumacher M, Sitruk-Ware R, De Nicola AF. Progesterone and progestins: neuroprotection and myelin repair. Curr Opin Pharmacol 2008;8:740–6
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011;11:159–70
   PubMedGoogle Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560–7
   PubMed Web of Science ®Google Scholar
• Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104:2826–31
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757–61
   PubMed Web of Science ®Google Scholar
• Williams JK, Cline JM, Honore EK, Delansorne R, Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998;179:1288–94
   PubMed Web of Science ®Google Scholar
• Nath A, Sitruk-Ware R. Different cardiovascular effects of progestins according to structure and activity. Climacteric 2009; 12(Suppl 1):96–101
   PubMedGoogle Scholar
• Simoncini T, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007;22:2325–34
   PubMed Web of Science ®Google Scholar
• Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. Faseb J 2007;21:265–73
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
   PubMed Web of Science ®Google Scholar
• Fu XD, Giretti MS, Goglia L, et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and Nestorone on breast cancer cell migration and invasion. BMC Cancer 2008;8:166
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions. US Preventive Services Task Force Recommendation Statement. Release Date: October 2012. http://www.uspreventiveservicestaskforce.org/uspstf12/menohrt/menohrtfinalrs.htm
   Google Scholar
• Stuenkel CA, Gass ML, Manson JE, et al. A decade after the Women’s Health Initiative – the experts do agree. J Clin Endocrinol Metab 2012;97:2617–8
   PubMed Web of Science ®Google Scholar
• Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–21
   PubMed Web of Science ®Google Scholar
• Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002;143:205–12
   PubMed Web of Science ®Google Scholar
• Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?Nat Clin Pract Cardiovasc Med 2008;5:387–95
   PubMedGoogle Scholar
• Schierbeck LL, Rejnmark L, Landbo-Tofteng C, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409 doi: 10.1136/bmj.e6409
   PubMed Web of Science ®Google Scholar